-The Hindu The much-awaited Drug (Prices Control) Order 2013 has disappointed millions of patients, as it lacks a fair formula to fix the price ceiling and leaves important drug classes out of regulation. The result: High out-of-pocket spending on medicines will continue As far as intentions go, the Drug (Prices Control) Order 2013 is aimed at making critical drugs affordable and available to the public, while preserving a rationale for manufacture by...
More »SEARCH RESULT
Govt bans popular diabetes drug and analgin -Rupali Mukherjee
-The Times of India MUMBAI: The government has banned three popular medicines-the widely prescribed anti-diabetes drug pioglitazone, painkiller analgin and anti-depressant deanxit-in the wake of health risks associated with them. While it's believed that pioglitazone can cause heart failure and increases the risk of bladder cancer, analgin has been discarded the world over on grounds of patient safety. Deanxit, on the other hand is a harmful combination, which has been long...
More »Prices of key drugs to be cut by up to half-Sushmi Dey
-The Business Standard NPPA to soon notify prices in line with new pharma pricing policy Some key cancer drugs, antibiotics and medicines to treat cardiovascular diseases and tuberculosis are set to become cheaper by up to 50 per cent within the next 45 days. The National Pharmaceutical Pricing Authority (NPPA) will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according...
More »Cancer medication as low as Rs 1,000/month on way -Malathy Iyer
-The Times of India MUMBAI: It's widely known that a month's dose of cancer drugs can cost lakhs, but what isn't common knowledge is that Tata Memorial Hospital's doctors are working on alternatives that could cost less than Rs 1,000 a month. Dubbed the metronomic treatment protocol, it comprises daily consumption of a combination of low-dose medicines that are cheap because they have been around for decades. "There is no need to...
More »Mumbai hospital advises doctors against prescribing Ranbaxy drugs-Malathy Iyer
-The Times of India MUMBAI: A Mumbai hospital has put up a notice advising its doctors to avoid prescribing drugs manufactured by Ranbaxy Laboratories. This comes a fortnight after Ranbaxy Laboratories agreed to pay a $500-million penalty to US authorities for "selling adulterated drugs" in the American market. It is not known whether the two are linked. Consultants at Jaslok Hospital said an advisory was put up at the receptionist's circular desk...
More »